Rogers Michael D. 4
4 · Pharmasset Inc · Filed Jan 17, 2012
Insider Transaction Report
Form 4
Pharmasset IncVRUS
Rogers Michael D.
Chief Development Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−40,000→ 0 totalExercise: $10.83Exp: 2019-10-14→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−50,000→ 0 totalExercise: $16.17Exp: 2020-10-14→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−52,500→ 0 totalExercise: $6.94Exp: 2017-11-01→ Common Stock (52,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−60,000→ 0 totalExercise: $83.52Exp: 2021-10-11→ Common Stock (60,000 underlying)
Footnotes (4)
- [F1]These options, which reflect the two-for-one stock split of the Issuer's common stock effective August 31, 2011 (the "Split") and which vested as to 25% on the first anniversary of the date of grant (November 1, 2007) and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Gilead Sciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $130.06 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F2]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 14, 2009) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.17 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F3]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 14, 2010) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $120.83 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F4]These options, which provided for vesting as to 25% on the first anniversary of the date of grant (October 11, 2011) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $53.48 per share, representing the difference between the exercise price of the options and $137.00 per share.